vs

Side-by-side financial comparison of INNODATA INC (INOD) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

INNODATA INC is the larger business by last-quarter revenue ($90.1M vs $44.6M, roughly 2.0× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). INNODATA INC runs the higher net margin — 16.5% vs -90.4%, a 107.0% gap on every dollar of revenue. On growth, INNODATA INC posted the faster year-over-year revenue change (54.4% vs 13.8%). Over the past eight quarters, INNODATA INC's revenue compounded faster (66.4% CAGR vs 7.3%).

Innodata Inc., formerly Innodata Isogen, Inc., is an American company that provides business process, technology and consulting services. The company also provides products that aim to help clients create, manage, use and distribute digital information.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

INOD vs PACB — Head-to-Head

Bigger by revenue
INOD
INOD
2.0× larger
INOD
$90.1M
$44.6M
PACB
Growing faster (revenue YoY)
INOD
INOD
+40.6% gap
INOD
54.4%
13.8%
PACB
Higher net margin
INOD
INOD
107.0% more per $
INOD
16.5%
-90.4%
PACB
Faster 2-yr revenue CAGR
INOD
INOD
Annualised
INOD
66.4%
7.3%
PACB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
INOD
INOD
PACB
PACB
Revenue
$90.1M
$44.6M
Net Profit
$14.9M
$-40.4M
Gross Margin
37.1%
Operating Margin
-92.3%
Net Margin
16.5%
-90.4%
Revenue YoY
54.4%
13.8%
Net Profit YoY
91.3%
-1802.7%
EPS (diluted)
$0.42
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INOD
INOD
PACB
PACB
Q1 26
$90.1M
Q4 25
$72.4M
$44.6M
Q3 25
$62.5M
$38.4M
Q2 25
$58.4M
$39.8M
Q1 25
$58.3M
$37.2M
Q4 24
$59.2M
$39.2M
Q3 24
$52.2M
$40.0M
Q2 24
$32.6M
$36.0M
Net Profit
INOD
INOD
PACB
PACB
Q1 26
$14.9M
Q4 25
$8.8M
$-40.4M
Q3 25
$8.3M
$-38.0M
Q2 25
$7.2M
$-41.9M
Q1 25
$7.8M
$-426.1M
Q4 24
$10.3M
$2.4M
Q3 24
$17.4M
$-60.7M
Q2 24
$-14.0K
$-173.3M
Gross Margin
INOD
INOD
PACB
PACB
Q1 26
Q4 25
38.3%
37.1%
Q3 25
40.8%
41.4%
Q2 25
39.4%
36.9%
Q1 25
39.9%
-3.7%
Q4 24
45.2%
25.6%
Q3 24
40.8%
25.0%
Q2 24
28.7%
16.5%
Operating Margin
INOD
INOD
PACB
PACB
Q1 26
Q4 25
15.1%
-92.3%
Q3 25
18.8%
-101.1%
Q2 25
15.3%
-112.8%
Q1 25
14.2%
-1154.5%
Q4 24
19.0%
-390.1%
Q3 24
21.9%
-160.3%
Q2 24
1.0%
-488.3%
Net Margin
INOD
INOD
PACB
PACB
Q1 26
16.5%
Q4 25
12.2%
-90.4%
Q3 25
13.3%
-98.9%
Q2 25
12.4%
-105.4%
Q1 25
13.3%
-1146.8%
Q4 24
17.4%
6.0%
Q3 24
33.3%
-151.9%
Q2 24
-0.0%
-481.3%
EPS (diluted)
INOD
INOD
PACB
PACB
Q1 26
$0.42
Q4 25
$0.26
$-0.11
Q3 25
$0.24
$-0.13
Q2 25
$0.20
$-0.14
Q1 25
$0.22
$-1.44
Q4 24
$0.35
$-0.44
Q3 24
$0.51
$-0.22
Q2 24
$0.00
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INOD
INOD
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$117.4M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$128.2M
$5.3M
Total Assets
$210.4M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INOD
INOD
PACB
PACB
Q1 26
$117.4M
Q4 25
$82.2M
$279.5M
Q3 25
$73.9M
$298.7M
Q2 25
$59.8M
$314.7M
Q1 25
$56.6M
$343.1M
Q4 24
$46.9M
$389.9M
Q3 24
$26.4M
$471.1M
Q2 24
$16.5M
$509.8M
Stockholders' Equity
INOD
INOD
PACB
PACB
Q1 26
$128.2M
Q4 25
$107.1M
$5.3M
Q3 25
$97.3M
$36.1M
Q2 25
$86.7M
$61.5M
Q1 25
$75.5M
$91.6M
Q4 24
$63.5M
$506.6M
Q3 24
$47.7M
$453.1M
Q2 24
$29.0M
$492.7M
Total Assets
INOD
INOD
PACB
PACB
Q1 26
$210.4M
Q4 25
$168.6M
$784.1M
Q3 25
$152.9M
$803.2M
Q2 25
$132.6M
$825.5M
Q1 25
$125.2M
$860.8M
Q4 24
$113.4M
$1.3B
Q3 24
$88.2M
$1.5B
Q2 24
$66.0M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INOD
INOD
PACB
PACB
Operating Cash FlowLast quarter
$37.3M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
2.50×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INOD
INOD
PACB
PACB
Q1 26
$37.3M
Q4 25
$12.9M
$-19.1M
Q3 25
$18.8M
$-18.7M
Q2 25
$4.2M
$-29.4M
Q1 25
$10.9M
$-44.1M
Q4 24
$17.2M
$-30.6M
Q3 24
$11.4M
$-45.5M
Q2 24
$-454.0K
$-54.3M
Free Cash Flow
INOD
INOD
PACB
PACB
Q1 26
Q4 25
$10.1M
$-19.9M
Q3 25
$14.5M
$-18.8M
Q2 25
$2.5M
$-29.9M
Q1 25
$8.5M
$-45.4M
Q4 24
$15.0M
$-32.3M
Q3 24
$9.9M
$-46.3M
Q2 24
$-3.2M
$-55.7M
FCF Margin
INOD
INOD
PACB
PACB
Q1 26
Q4 25
13.9%
-44.6%
Q3 25
23.2%
-48.9%
Q2 25
4.3%
-75.3%
Q1 25
14.6%
-122.3%
Q4 24
25.3%
-82.3%
Q3 24
19.0%
-115.7%
Q2 24
-9.8%
-154.8%
Capex Intensity
INOD
INOD
PACB
PACB
Q1 26
Q4 25
3.9%
1.9%
Q3 25
6.8%
0.2%
Q2 25
2.9%
1.4%
Q1 25
4.0%
3.7%
Q4 24
3.7%
4.1%
Q3 24
2.8%
2.0%
Q2 24
8.4%
4.1%
Cash Conversion
INOD
INOD
PACB
PACB
Q1 26
2.50×
Q4 25
1.46×
Q3 25
2.25×
Q2 25
0.59×
Q1 25
1.40×
Q4 24
1.67×
-12.93×
Q3 24
0.65×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INOD
INOD

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons